Trial Profile
Phase II Trial of Primary Endocrine Therapy With Combination of Fulvestrant or an Aromatase Inhibitor and Palbociclib in Elderly Patients With Hormone Responsive Breast Cancer Who Have Inoperable Tumor Or Operable Tumor But Cannot Undergo Surgery Due to Frailty Or Who Refuse Surgery
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 03 May 2023 Planned End Date changed from 31 Jul 2020 to 31 Dec 2024.
- 03 May 2023 Planned primary completion date changed from 31 Jul 2020 to 31 Dec 2023.
- 18 Dec 2019 Planned primary completion date changed from 1 Jul 2020 to 31 Jul 2020.